EXAS
EXACT Sciences Corporation
NASDAQ: EXAS · HEALTHCARE · DIAGNOSTICS & RESEARCH
$104.91
+0.00% today
Updated 2026-03-24
Market cap
$20.03B
P/E ratio
—
P/S ratio
6.17x
EPS (TTM)
$-1.10
Dividend yield
—
52W range
$39 – $1,878
Volume
2.7M
EXACT Sciences Corporation (EXAS) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$104.91
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $2.1B | $2.5B | $2.8B | $3.2B | $3.8B | $4.4B | $5.2B | $6.1B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 16.84% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -6.40%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.